Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $2.15. Advaxis shares last traded at $2.15, with a volume of 1,840 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of Advaxis in a research report on Monday, August 22nd. They set a "sell" rating on the stock.
Get Advaxis alerts:Advaxis Stock Performance
The stock has a market capitalization of $3.90 million, a price-to-earnings ratio of -21.50 and a beta of 2.07. The company has a 50 day simple moving average of $3.37.
Advaxis Company Profile
(Get Rating)Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
See Also
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.